Drug
BMS201038 clinical trials
Also written lomitapide, AEGR-733, Juxtapid and BMS-201038.
- studies test it
- 15
- open now
- 0
- in phase 3
- 5
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BMS201038 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)CompletedPhase 3Amryt PharmaNCT04681170Written as Lomitapide
- Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy SubjectsCompletedPhase 1Aegerion Pharmaceuticals, Inc.NCT01915771Written as lomitapide
- Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.CompletedPhase 1Aegerion Pharmaceuticals, Inc.NCT02080455Written as lomitapide
- Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female SubjectsCompletedPhase 1Aegerion Pharmaceuticals, Inc.NCT02080468Written as lomitapide
- Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-CCompletedPhase 1Aegerion Pharmaceuticals, Inc.NCT01760187Written as lomitapide
- Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering TherapyCompletedPhase 3Aegerion Pharmaceuticals, Inc.NCT02173158Written as lomitapide
- Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 3Aegerion Pharmaceuticals, Inc.NCT00943306Written as lomitapide
- AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate HypercholesterolemiaCompletedPhase 2Aegerion Pharmaceuticals, Inc.NCT00474240Written as AEGR-733 5 mg
- A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)CompletedPhase 3Aegerion Pharmaceuticals, Inc.NCT00730236Written as AEGR-733
- Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRSCompletedPhase 2Aegerion Pharmaceuticals, Inc.NCT00559962Written as AEGR-733
- Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in HypercholesterolemiaCompletedPhase 2Aegerion Pharmaceuticals, Inc.NCT00690443Written as AEGR-733
- Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering TherapyWithdrawnPhase 3Aegerion Pharmaceuticals, Inc.NCT02765841Written as Lomitapide
- A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs SprinkledCompletedPhase 1Aegerion Pharmaceuticals, Inc.NCT02044419Written as lomitapide
- The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate HypercholesterolemiaCompletedPhase 2Aegerion Pharmaceuticals, Inc.NCT00405067Written as BMS-201038 (AEGR-733)
- Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) InhibitorCompletedPhase 2Aegerion Pharmaceuticals, Inc.NCT01556906Written as Lomitapide
Codes
What other systems call BMS201038 · ClinicalTrials.gg INT004528
Also registered as lomitapide (UNII 82KUB0583F · RxNorm 1364479) and lomitapide mesylate (UNII X4S83CP54E · RxNorm 1364478).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.